Atlas Capital Advisors Inc. Sells 100 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Atlas Capital Advisors Inc. lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 25.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 290 shares of the medical research company’s stock after selling 100 shares during the quarter. Atlas Capital Advisors Inc.’s holdings in IQVIA were worth $57,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank bought a new stake in shares of IQVIA during the fourth quarter worth $336,041,000. Raymond James Financial Inc. acquired a new position in shares of IQVIA during the fourth quarter worth approximately $236,120,000. American Century Companies Inc. grew its stake in shares of IQVIA by 396.0% during the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock valued at $222,987,000 after purchasing an additional 905,960 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Finally, Nordea Investment Management AB lifted its holdings in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on IQV shares. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Truist Financial reissued a “buy” rating and set a $263.00 price target (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Citigroup reduced their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Finally, Bank of America cut their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Trading Down 7.8 %

NYSE:IQV opened at $154.63 on Friday. The business’s 50-day simple moving average is $189.67 and its 200-day simple moving average is $203.82. IQVIA Holdings Inc. has a fifty-two week low of $154.35 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market capitalization of $27.26 billion, a PE ratio of 20.62, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.